Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
An autosomal dominant tumor predisposition disorder caused by pathogenic variants in the TMEM127 gene, characterized by an increased risk of paraganglioma and pheochromocytoma, as well as an increased risk of renal cell carcinoma.
No clinical trials have been registered for TMEM127-related tumor predisposition.
4 publications have been identified in PubMed for TMEM127-related tumor predisposition. Research spans Review / Meta-Analysis (100%).
Rednam SP (2025). [PMID: 40549645](https://pubmed.ncbi.nlm.nih.gov/40549645/). *Clin Cancer Res*. [Review / Meta-Analysis]
Michalczewska A (2025). [PMID: 40176333](https://pubmed.ncbi.nlm.nih.gov/40176333/). *Med Sci Monit*. [Review / Meta-Analysis]
Torresan F (2024). [PMID: 39000254](https://pubmed.ncbi.nlm.nih.gov/39000254/). *Int J Mol Sci*. [Review / Meta-Analysis]
Mauer Hall CB (2024). [PMID: 39539798](https://pubmed.ncbi.nlm.nih.gov/39539798/). *Endocr Oncol*. [Review / Meta-Analysis]
Data assembled from 2 of 12 sources · Last updated Sep 20, 2026, 3:07 PM UTC
Common questions about TMEM127-related tumor predisposition